Periadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
Periadjuvant pembrolizumab may improve outcomes over adjuvant pembrolizumab alone in patients with resectable stage III-IV melanoma, a phase 2 study suggests.
Investigators in Spain developed an algorithm for diagnosing melanomas that had good diagnostic accuracy and was easier to perform than other diagnostic algorithms.
Researchers compared all-cause and melanoma-specific mortality in patients aged 15 to 39 years and 40 to 64 years with advanced melanoma.
Lower percentage of individuals seen with history of past or present melanoma, any type of skin cancer among regular users.
Primary tumor ulceration, head/neck location, and Breslow thickness >4 mm predict worse survival in teens.
Companies announced that the vaccine performed well in a small study of patients who had the cancer surgically removed.
A study in Australia explored the factors that increase the risk for a second primary melanoma.
Significantly longer progression-free survival seen with infusion of tumor-infiltrating lymphocytes versus ipilimumab.
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment.
Younger age at diagnosis, Clark level II linked to low risk for death among patients with stage I lesions, negative clinical nodes.